相关研究结果于2022年11月10日在线发表在Nature期刊上,论文标题为“Non-viral precision T cell receptor replacement for personalized cell therapy”。论文通讯作者为加州大学洛杉矶分校的Antoni Ribas博士、PACT制药公司的Stefanie J. Mandl博士和Susan P. Foy博士。 图片来自Thomas Splettstoesser (Wikipedia, CC BY-...
在一项新的研究中,来自美国德克萨斯大学MD安德森癌症中心的研究人员报告称,使用经过编程识别隐球菌属真菌的嵌合抗原受体(CAR)T细胞(CAR-T)在体外和小鼠中都能有效地对抗感染。相关研究结果近期发表在Cytotherapy期刊上,论文标题为“Glucuronoxylomannan in the Cryptococcus species capsule as a target for Chimeric Antige...
④回输:把扩增好的CAR-T细胞回输到病人体内。 ⑤监控:严密监护病人,尤其是控制前几天身体的剧烈反应。 The process of chimeric antigen receptor T-cell therapy [2] 参考文献: [1]引自http://us.xinhuanet.com/2017-10/20/c_129723692.htm?baike [2]引自https://en.wikipedia.org/wiki/Chimeric_antige...
"Prior to the advent of CAR-T cell therapy, patients who had failed two lines of chemotherapy had a very poor survival of around six months," says Dr. Iqbal. Receiving CAR-T cell therapy can take a few weeks as a patient's T cells, which normally help fight off infections, are colle...
Micrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0 Patients with multiple myeloma treated with idecabtagene vicleucel, known as "ide-cel," a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall surviva...
可以看出继CAR-T之后,CAR-NK也在跃跃欲试准备问世,不过在你仍然关注CAR-T、CAR-NK细胞的时候,CAR-NKT也要来啦!随着CAR家族的成员不断扩大,希望在不久的未来CAR家族的价格不再昂贵到负担不起,各家族成员攻克疾病的覆盖范围也越来越广!而CAR-NK也许就是打破...
3. Zhang,C., et al., Engineering CAR-T cells.Biomark Res, 2017. 5: p. 22. 4. Levine,B.L., et al., Global Manufacturing of CART Cell Therapy. Mol Ther Methods Clin Dev, 2017. 4: p. 92-101. 5. Yip,A. and R.M. Webster, Th...
(Freedom to Operate,FTO),凯特公司围绕着核心技术进行了全面的专利的自由实施度调查,并通过专利许可的方式获得了来自Cell Genesys(US6319494B1,CAR-T的治疗方法专利)、Cabaret Biotech Ltd(US7741765B1,编码CAR的多核苷酸)、National Institutes of Health(NIH)、魏茨曼科学院(Weizmann Institute of Science)以及洛杉矶...
近日,一篇发表在国际杂志The Lancet上题为“Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study”的研究报告中,来自美国Sarah Cannon研究所等机...
ACT:过继细胞疗法(adoptive cell therapy),指 将体外活化和扩增的自体或异体免疫效应细胞输注患者体内的治疗方法 。大意是取患者本人或他人的免疫细胞,经实验室改造和(或不改造)培养后输入患者体内,经过处理的免疫细胞在数量上和功能上的变化使其具有更强的治疗疾病(主要是肿瘤)的作用。